ImmunityBio, Inc. (IBRX)
9.18
-0.82
(-8.20%)
USD |
NASDAQ |
Oct 16, 16:00
9.16
-0.02
(-0.22%)
After-Hours: 20:00
ImmunityBio Research and Development Expense (Annual) : 216.56M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 216.56M |
| December 31, 2024 | 188.14M |
| December 31, 2023 | 213.85M |
| December 31, 2022 | 229.89M |
| December 31, 2021 | 195.96M |
| December 31, 2020 | 64.48M |
| December 31, 2019 | 48.88M |
| Date | Value |
|---|---|
| December 31, 2018 | 53.42M |
| December 31, 2017 | 39.78M |
| December 31, 2016 | 26.55M |
| December 31, 2015 | 11.43M |
| December 31, 2014 | 1.595M |
| December 31, 2013 | 0.446M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Moderna, Inc. | 2.917B |
| Sarepta Therapeutics, Inc. | 1.493B |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |